Replies to post #25278 on Ariad Pharmaceuticals Inc fka ARIA

[JJM760]

From my perspective, the shareholders have been taking a "temporary hit" for more than 20 years now. The market cap is over $3 billion because of the enormous amount of shares outstanding. I think from the markets perspective you now move from being a small time R&D biotech to a drug company by getting big boy financing like the rest of the world does. We all pay for the cost of capital in business. I think it's time to stop diluting the shareholders. If Ponatinib is the Superdrug that Ariad feels it is, this interest will be a nonevent in 5 years.

That's my two cents.

[iandy]

Please explain why the company taking on 300 million worth of debt will be viewed as more of a positive than having the shareholders take a temporary hit on a dilution that leaves the company 300 million stronger without incurring any company debt.

Shareholders are in no mood to see a further dilution here.
The stock could test 16 or even 15.
I think Harvey knows that and doesn't want to see it happen.
The interest payments are not going to adversely effect the stock unless Iclusig sales disappoint, IMHO.

There were only like two of us (here) that supported the last offering. The major investors loved it.
I imagine the major investors are more in favor of a loan here than further dilution.